- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04192877
Validity and Inter-rater Reliability fo the Vagus Nerve Neurodynamic Test Among Healthy Subjects
December 16, 2019 updated by: Giacomo Carta, University of Turin, Italy
Validation and Inter-rater Reliability of the Vagus Nerve Neurodynamic Test Among Healthy Subjects.
Vagus nerve neurodynamic test (VN-NDT) will be validated detecting the changes in vagus nerve anatomical position due to the combination of movements of the test.
Healthy subjects will be enrolled and screened for neurological problems.
A checklist for autonomic dysfuntion symptoms will be administered and heart rate at rest will be measured.
Inter-rater reliability will be assessed comparing positive and negative cases identified by two blinded assessors, one expert and one novice.
It will also be monitored and compared the amount of motion induced by the expert and the novice assessors during the VN-NDT admimistration.
If symptoms will be produced by the VN-NDT using a pain drawing tool it will be defined the qualitiy and the location of them.
Accuracy of the VN-NDT will be tested in the autonomic dysfunction symptom detection.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
_A growing body of evidence has shown that the Vagus Nerve (VN) is not only the main anatomical structure responsible for the brain and guts communication but is also a target for many interventions in which drugs or classic treatments have failed.
The VN cervical tract stimulation has reported positive results for high social burden problems like acute and chronic pain, psychiatric diseases, disturbs of consciousness and epilepsy.
Also, it is well known that the selective tension of the Peripheral Nervous System, or neurodynamic test (NDT), is useful for diagnosis and treatment of neuropathic diseases and pain.
Over the last 30 years NDTs were validated for upper and lower limb nerves but nowadays a VN-NDT is lacking and could be a potential alternative in diagnosis and treatment for critical or neglected conditions.
Methods_ An estimated sample of 30 healthy participants will complete a questionnaire on vagal symptoms and perceived health status.
A neurological assessment of the cervical tract will be performed before the test.
The VN-NDT will be administered through a standardized sequence of physiological neck movements.
Symptoms and heart rate (HR) will be monitored.
Validity of NDT will be tested with ultrasonography assessment (C6-VN distance) during the tests administered by an expert and a novice.
Motion of both assessors and subjects will be tracked through an infra-red optoelectronic system.
Inter-examiner accordance will be obtained and comparisons between assessors' positive and negative tests due to symptoms provocation and reduction (Cohen's Kappa) will be performed.
A two-way analysis of variance (ANOVA) will be performed with factors experience and side tested (2 × 2).
Receiver operating characteristic (ROC) curves will be adopted to define the accuracy, sensitivity, specificity, positive and negative likelihood ratios of the VN-NDT in autonomic dysfunction symptoms detection and on perceived health status.Results_ It is expected to determine the inter-examiner accordance and to not detect significant assessors effects on test results.
It is also expected to detect a change of the C6-VN distance and HR during the test and to estimate the accuracy of the test for autonomic dysfunctions detection.Conclusions_ Normative physiological values parameter variations at the administration of the VN-NDT are fundamental to determine the hallmarks needed to screen clinical and preclinical conditions involving autonomic dysfunctions_
Study Type
Observational
Enrollment (Actual)
30
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
MI
-
Milano, MI, Italy, 20100
- Movement and Posture Analysis Lab
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 68 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
Healthy subjects that want to participate in the study
Description
Inclusion Criteria:
- Subjects aged between 18 and 70 years old
- Subjects that have signed the written informed consent
Exclusion Criteria:
- Subjects with significant neck pain or headache (with NRS greater than 3/10)
- Pregnancy
- Recent neck surgery or significant trauma in the preceding 3 months
- Cancer or inflammatory disorders spinal cord or cauda equina signs
- Widespread neurological disorders affecting the tone of upper limb and neck muscles
- Underlying diseases, such as diabetes mellitus.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Cross-Sectional
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Experimental
30 healthy subjects from both genders, aged between 18 and 60 years will be screened for neurological deficits.
If neurological examination will be negative markers for motion capture, analysis will be placed on the chest and shoulders and a rubber band, with 3 markers, will be placed on the forehead.
The subjects will be invited to lay on a medical table and heart rate (HR) will be assessed at rest.
The vagus nerve neurodynamic test (VN-NDT) will be performed by an expert and a novice, in a random order, and under ultrasound imaging (USI).
Assessors will be blinded to their results.
Heart rate (HR) of the subjects will be monitored and a pain drawaing tools will be used to describe and locate the symptoms induced during the test administration.
|
The VN-NDT has been developed starting from the VN morphology selecting the physiological movements that induce the greater mechanical tension on the nerve.
The subjects will be assessed supine on an examination table with assessors standing at the cranial short side of the table.
Upper cervical flexion and contralateral lateral flexion had been selected for loading the intracranial portion.
The ipsilateral neck rotation had been selected for loading the cervical tract.
Keeping the subject's head in the final movements combination gentle movements of the upper abdomen caudally and cranially had been selected for loading the thoracic tract and used as discrimination maneuver.
The test will be declared positive (indicating abnormal responses) if symptoms will be felt in anatomical regions other than the neck on the same side of the test and discrimination maneuvers changed the subject's symptoms indicating a neurogenic source, otherwise it will be declared negative.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Vagus nerve neurodynamic test (VN-NDT)
Time Frame: The test will be administered twice for each side, once by an expert and once by a novice.
|
combination of physiological movements of the neck (upper cervical flexion, contralateral lateral flexion, ipsilteral rotation and gentle movements of the upper abdomen caudally and cranially to increase tension on the thoracic tract of the VN)
|
The test will be administered twice for each side, once by an expert and once by a novice.
|
Ultrasound imaging (USI)
Time Frame: USI will be administered twice for each side, once by an expert and once by a novice.
|
Axial scans will be obtained using the inferior margin of the thyroid as initial reference from which the probe will be moved laterally to the region of the transverse processes.
The probe will also be moved cranially till anterior tubercle of C6 detection.
Distance between VN and C6 anterior tubercle will be measured at rest and at the final position of the VN-NDT to quantify the lateralization or proximalization of the VN induced by the test.
|
USI will be administered twice for each side, once by an expert and once by a novice.
|
Motion capture analysis (MCA)
Time Frame: MCA will be used for the duration the VN-NDT administered twice for each side, once by an expert and once by a novice.
|
Throughout the whole duration of VN-NDT with real-time USI assessment, the three-dimensional head orientation of the subjects will be recorded at 100 Hz by means of an optoelectronic motion capture system (Smart-DX, BTS S.p.A., Milano, Italy).
A cluster with three retroreflective markers (diameter: 15 mm) will be secured on the subject's head using an elastic band; three additional markers will be fixed on the acromia and on the sternum.
The time event corresponding to the obtainment of a proper USI in the rest and final head positions will be manually annotated upon explicit communication by the USI operator.System calibration will be conducted according to the manufacturers' guidelines and returned an average error in marker position of 0.35 mm, on a working volume of 2.6 x 1.8 x 2.5 m3
|
MCA will be used for the duration the VN-NDT administered twice for each side, once by an expert and once by a novice.
|
Short-term autonomic response (STAR)
Time Frame: HR will be measured at rest and end of the VN-NDT for each sides (4 times by an expert and 4 times by a novice).
|
The heart rate will be taken (HR) as reference comparing the HR from rest to the HR keeping the head and neck of the subjects in the end position of the VN-NDT for 5 seconds
|
HR will be measured at rest and end of the VN-NDT for each sides (4 times by an expert and 4 times by a novice).
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Checklist for symptoms related to autonomic peripheral neuropathy (APN) and VN dysfunction
Time Frame: The checklist will be administred once. Before the neurological examination
|
A checklist for the presence of any symptoms and signs reported in literature to be linked with APN and VN diseases was fulfilled by every participant (Orthostatic Hypotension; Nausea; Digestion Alterations; Breathing Alterations (shortness of breath); Voice Changes; Altered deglutition; Perceived augmented HR;Perceived reduced HR; Burning sensation in the stomach; Constipation; Diarrheal; Vomit; Augmented lacrimation; Reduced lacrimation; Augmented salivation; Reduced salivation; Head and neck sweating attacks; Head and neck skin dryness; Sleep alteration)
|
The checklist will be administred once. Before the neurological examination
|
Perceived health status (PHS)
Time Frame: The PHS will be administred once. Before the neurological examination
|
A 11 point Likert scale was administered to assess the Perceived health status (100 the best 0 the worst health status ever)
|
The PHS will be administred once. Before the neurological examination
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Giacomo Carta, Msc, University of Turin, Italy
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 5, 2019
Primary Completion (Actual)
December 12, 2019
Study Completion (Actual)
December 16, 2019
Study Registration Dates
First Submitted
December 5, 2019
First Submitted That Met QC Criteria
December 5, 2019
First Posted (Actual)
December 10, 2019
Study Record Updates
Last Update Posted (Actual)
December 17, 2019
Last Update Submitted That Met QC Criteria
December 16, 2019
Last Verified
December 1, 2019
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 139870-14/03/2019
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Yes
IPD Plan Description
There is a plan to make IPD and related data dictionaries available.
All of the individual particiapnt data collected during the trial will be shared after deidentification
IPD Sharing Time Frame
Immediately following the publication.
No end date.
IPD Sharing Access Criteria
Anyone who wishes to access the data.
IPD Sharing Supporting Information Type
- Study Protocol
- Statistical Analysis Plan (SAP)
- Informed Consent Form (ICF)
- Clinical Study Report (CSR)
- Analytic Code
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diagnoses Disease
-
Inspirata Europe Ltd.CompletedDiagnoses DiseaseUnited Kingdom
-
Shanghai Chest HospitalUnknownDiagnoses DiseaseChina
-
Nazan Kocak TopbasMersin UniversityNot yet recruiting
-
Brigham and Women's HospitalCricoActive, not recruiting
-
Istanbul Bilgi UniversityUnknown
-
Hospital do CoracaoCompletedInpatient Facililty DiagnosesBrazil
-
Institute of Liver and Biliary Sciences, IndiaCompleted
-
Nagaoka Red Cross HospitalUnknownOther Diagnoses and ConditionsJapan
-
Anhui Medical UniversityTechnion, Israel Institute of TechnologyNot yet recruitingCancer | Diagnoses Disease | Volatile Organic Compounds
Clinical Trials on Vagus Nerve Neurodynamic test
-
Ugur SozluGazi UniversityCompleted
-
Northwell HealthEnrolling by invitationAutonomic Nervous System Diseases | Autonomic Dysfunction | Autonomic Imbalance | Vagus Nerve Autonomic DisorderUnited States
-
Peking University People's HospitalEnrolling by invitationChemotherapy-induced Peripheral Neuropathy | CIPNChina
-
Northwell HealthCompletedStroke | Hemiparesis | Cerebrovascular Accident (CVA)United States
-
Severance HospitalRecruitingCough | Thoracic Surgery | Nerve BlockKorea, Republic of
-
University Hospital, GhentResearch Foundation FlandersCompletedEpilepsyBelgium, United States
-
Baylor Research InstituteUniversity of Texas Southwestern Medical Center; Wings for Life; The University... and other collaboratorsRecruitingSpinal Cord Injuries | Upper Extremity ParesisUnited States
-
Baylor Research InstituteNational Institute of Neurological Disorders and Stroke (NINDS); University... and other collaboratorsRecruitingStroke | Ischemic Stroke | Hemorrhagic Stroke | Upper Extremity Paresis | Chronic StrokeUnited States
-
University Medical Centre LjubljanaCompletedIschemic Heart Disease | Arterial HypertensionSlovenia